BioSpace News Archive

Common Sensing, developer and manufacturer of injectable medicine hardware and software tools, announced the appointment of Kevin Schmid as Chief Executive Officer.

The European Investment Bank today agreed a EUR 30 million facility to support investment by Dublin based biotech company, Nuritas, to further increase and accelerate development of artificial intelligence and DNA analysis to improve global healthcare.

Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation for apraglutide for the treatment of short bowel syndrome (SBS). “

United PF Partners (United PF), the largest Planet Fitness (NYSE: PLNT) franchisee, recently reached a key milestone as they officially became the first franchisee in the system to own and operate more than 100 Planet Fitness clubs

Chef videos augment AKF’s phosphorus education initiatives to help kidney patients manage their diets

A recent Arthritis Research Canada study has revealed systemic autoimmune rheumatic diseases (SARDS) place significant economic strain on the paid and unpaid workforce in the form of excess productivity costs.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Adam Cutler to the Company’s board of directors, effective December 1, 2018.

IQVIA Holdings Inc. announced today the launch of an underwritten, secondary public offering of 6,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc. and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,000,000 shares (the “Repurchase”).

Trial represents the pinnacle of the MMRF’s end-to-end precision medicine model, which identified and validated the targets being studied in MyDRUG

Concordia International Corp. today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to change its name from Concordia International Corp. to ADVANZ PHARMA Corp.